| __timestamp | Bio-Techne Corporation | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 60716000 | 7751000 |
| Thursday, January 1, 2015 | 119401000 | 10251000 |
| Friday, January 1, 2016 | 140879000 | 9575000 |
| Sunday, January 1, 2017 | 199243000 | 10912000 |
| Monday, January 1, 2018 | 240636000 | 11049000 |
| Tuesday, January 1, 2019 | 264359000 | 11646000 |
| Wednesday, January 1, 2020 | 260583000 | 13265000 |
| Friday, January 1, 2021 | 324951000 | 25805000 |
| Saturday, January 1, 2022 | 372766000 | 35182000 |
| Sunday, January 1, 2023 | 378378000 | 94999000 |
| Monday, January 1, 2024 | 396826000 |
Unleashing insights
In the ever-evolving biotech industry, understanding financial health is crucial. This chart compares the Selling, General, and Administrative (SG&A) expenses of Bio-Techne Corporation and Viridian Therapeutics, Inc. from 2014 to 2023. Bio-Techne, a leader in the field, has seen its SG&A expenses grow by over 550% from 2014 to 2023, reflecting its expanding operations and market reach. In contrast, Viridian Therapeutics, a smaller player, experienced a more modest increase of approximately 1,125% over the same period, albeit from a much smaller base. Notably, Viridian's expenses surged in 2023, indicating potential strategic shifts or expansions. Missing data for 2024 suggests ongoing developments. This financial snapshot offers a glimpse into the strategic priorities and growth trajectories of these two biotech firms, highlighting the dynamic nature of the industry.
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Bio-Techne Corporation
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Viridian Therapeutics, Inc.
Selling, General, and Administrative Costs: Amgen Inc. vs Viridian Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc. or Bio-Techne Corporation: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Genmab A/S or Viridian Therapeutics, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Bio-Techne Corporation and Blueprint Medicines Corporation
Selling, General, and Administrative Costs: Bio-Techne Corporation vs Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Bio-Techne Corporation and Pharming Group N.V.
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Catalyst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Bio-Techne Corporation vs Xencor, Inc.
Selling, General, and Administrative Costs: Mesoblast Limited vs Viridian Therapeutics, Inc.